It's the same scenario as the enox approvals. Momenta never matched it's post approval pop did it?
You fail to understand the larger picture of M356 approval. Not only will MNTA generate significant cash flows for a long period of time however it'll do something even greater... it'll cement MNTA's technical prowess with the investment community and the FDA. Nobody will be able to say MNTA's a one-trick pony and this should lead to the street attributing substantially more value to MNTA's partnership with Baxter.
You can rip on MNTA management all you want however MNTA would be generating substantial cash flow had it not been for the FDA and our friends at Ampha cheating their way into approval. Had this not happened MNTA would easily be above its post Lovenox pop with a massive war chest of cash.
IMO, approval of M356 moves MNTA into the $30-40 range for the foreseeable future. No Bill Marth sell-off this time...
""That is a strange prediction. So MNTA gets a boost upon Copaxone approval the doesn't rise as cash comes in from Copaxone sales.""
{{It's the same scenario as the enox approvals. Momenta never matched it's post approval pop did it? }}
It is fundamentally different. With Lovenox, there was always the chance another generic would come out and dramatically cut MNTA's percentage of revenues. The MNTA Copaxone deal with Novartis is unaffected by another generic.
Market Data 
Markets 
AI
